Thompson Tommy G 4

4 · UNITED THERAPEUTICS Corp · Filed Mar 26, 2026

AI-generated summary of this filing

Updated Mar 26, 2026

United Therapeutics (UTHR) Director Tommy Thompson Exercises Options, Sells Shares

What Happened

Tommy G. Thompson, a director of United Therapeutics (UTHR), exercised options to acquire 2,000 shares at $101.80 per share (total cost $203,600) on 2026-03-26 and sold a total of 2,000 shares in open-market trades the same day for approximately $1,078,332.
The sales were reported in three blocks: 275 shares at a weighted avg $537.62 ($147,845), 1,414 shares at a weighted avg $539.25 ($762,493), and 311 shares at a weighted avg $540.17 ($167,994). The Form 4 also reports a separate derivative conversion/disposition of 2,000 shares with $0 proceeds.

Key Details

Transaction date: 2026-03-26.
Exercise: 2,000 shares at $101.80 ($203,600). Sales: 2,000 shares total for ~$1,078,332 (see per-block prices above).
Shares owned after transaction: Not specified in the provided filing.
Footnotes:
- F1: Filing includes 880 shares to be issued ~July 8, 2026 from a July 7, 2023 RSU deferral.
- F2–F4: Sales executed in multiple trades; reported prices are weighted averages (ranges provided in the footnotes).
Timeliness: Filing date (2026-03-26) matches the report date (2026-03-26); the filing is not shown as late.

Context

This is effectively a cashless exercise pattern: options were exercised and an equal number of shares were sold the same day, generating net proceeds after exercise cost.
The separate derivative line showing 2,000 shares disposed at $0 is reported on the Form 4; the filing does not explain the mechanics—no assumptions about intent are made here.
Sales by officers/directors are common and may reflect routine portfolio or tax-management activity; purchases generally carry more affirmative insider bullish signal than routine sales.

Form 4

Period: 2026-03-26

Director

Transactions

Exercise/Conversion
Common Stock
[F1]
2026-03-26$101.80/sh+2,000$203,600→ 10,480 total
Sale
Common Stock
[F2][F1]
2026-03-26$537.62/sh−275$147,845→ 10,205 total
Sale
Common Stock
[F3][F1]
2026-03-26$539.25/sh−1,414$762,493→ 8,791 total
Sale
Common Stock
[F4][F1]
2026-03-26$540.17/sh−311$167,994→ 8,480 total
Exercise/Conversion
Stock Option
2026-03-26−2,000→ 0 total
Exercise: $101.80From: 2017-06-21Exp: 2026-06-21→ Common Stock (2,000 underlying)

Holdings

Footnotes (4)

[F1]Includes 880 shares of common stock to be issued on or about July 8, 2026, as the result of the July 7, 2023 vesting of RSUs for which the reporting person elected to defer receipt of shares.
[F2]This transaction was executed in multiple trades at prices ranging from $537.43 to $538.36. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F3]This transaction was executed in multiple trades at prices ranging from $538.63 to $539.49. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
[F4]This transaction was executed in multiple trades at prices ranging from $539.64 to $540.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Signature

/s/ John S. Hess, Jr. under Power of Attorney|2026-03-26

1 file